351-54-2

Basic information

• Product Name: 3-Fluoro-4-methoxybenzaldehyde
• Synonyms: 3-FLUORO-P-ANISALDEHYDE;3-FLUORO-4-ANISALDEHYDE;3-FLUORO-4-METHOXYBENZALDEHYDE;3-fluoro-para-anisaldehyde;3-Fluoro-4-Methoxybenzaldehyde/3-Fluoro-P-Anisaldehyde/M-Fluoro-P-Anisaldehyde/;3-Fluoroanisaldehyde;3-Fluoro-4-methoxybenzaldehyde,98%;3-fluoro-4-methoxybenzaldehyde(SALTDATA: FREE)
• CAS NO: 351-54-2
• Molecular Formula: C₈H₇FO₂
• Molecular Weight: 154.14
• EINECS: 206-514-3
• Product Categories: FINE Chemical & INTERMEDIATES;Aromatic Aldehydes & Derivatives (substituted);Benzaldehyde;Miscellaneous;Adehydes, Acetals & Ketones;Anisoles, Alkyloxy Compounds & Phenylacetates;Fluorine Compounds;Aldehydes;Aryl Fluorinated Building Blocks;Building Blocks;C8;C8-C12;Carbonyl Compounds;Chemical Synthesis;Fluorinated Building Blocks;Organic Building Blocks;Organic Fluorinated Building Blocks;Other Fluorinated Organic Building Blocks;Fluorine series
• Mol File: 351-54-2.mol

Chemical Properties

• Melting Point: 34-35 °C(lit.)
• Boiling Point: 129-132°C 11mm
• Flash Point: >230 °F
• Appearance: white to light yellow low melting crystalline mass
• Density: 1.192 g/cm³
• Vapor Pressure: 0.000619mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• Sensitive: Air Sensitive
• BRN: 1942621
• CAS DataBase Reference: 3-Fluoro-4-methoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Fluoro-4-methoxybenzaldehyde(351-54-2)
• EPA Substance Registry System: 3-Fluoro-4-methoxybenzaldehyde(351-54-2)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-22
• Safety Statements: 37/39-26-36
• WGK Germany: 3
• HazardClass: IRRITANT, AIR SENSITIVE
• Hazardous Substances Data: 351-54-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Fluoro-4-methoxybenzaldehyde is used as a reagent for the synthesis of resveratrol derivatives, which are potent inhibitors of lysine specific demethylase 1 (LSD1). LSD1 is a therapeutic target for cancer treatment and other related diseases, making 3-Fluoro-4-methoxybenzaldehyde valuable in the development of novel cancer therapies.
Used in Medicinal Chemistry:
3-Fluoro-4-methoxybenzaldehyde is also used as a reagent for the synthesis of substituted pyrazolyl piperidine derivatives. These derivatives exhibit antiplatelet aggregation activity in the human body, which can be beneficial in the prevention and treatment of cardiovascular diseases, such as thrombosis and atherosclerosis.

InChI:InChI=1/C13H11FS/c14-12-8-6-11(7-9-12)10-15-13-4-2-1-3-5-13/h1-9H,10H2

Upstream product

• 351-52-0 3-fluoro-4-methoxybenzyl chloride 
• 399-55-3 2-fluoro-1-methoxy-4-methylbenzene 
• 331-62-4 3-fluoro-4-methoxybenzonitrile 
• 331-61-3 3-fluoro-4-methoxybenzyl bromide 
• 7647-01-0 hydrogenchloride 
• 7446-70-0 aluminium trichloride 
• 321-28-8 1-fluoro-2-methoxybenzene 
• 71-43-2 benzene 
• 75-15-0 carbon disulfide 
• 100-97-0 hexamethylenetetramine 
• 123-11-5 4-methoxy-benzaldehyde 
• 3907-15-1 3-fluoro-4-methoxybenzoylchloride 
• 1191-17-9 1,1-dichloromethyl-methyl ether 
• 34036-07-2 3,4 difluorobenzaldehyde 

Downstream Products

• 397-66-0 4-((Z)-3-fluoro-4-methoxy-benzylidene)-2-phenyl-4H-oxazol-5-one 
• 717-79-3 3-amino-3-(3-fluoro-4-methoxy-phenyl)-propionic acid 
• 147906-08-9 (E)-3-(3-fluoro-4-methoxyphenyl)acrylic acid 
• 403-20-3 3-fluoro-p-anisic acid 
• 320-70-7 3-fluoro-4-methoxy-5-nitro-benzaldehyde 
• 63305-86-2 3,β,β,-Trifluoro-4-methoxystyrol 
• 144293-97-0 Isonicotinic acid [1-(3-fluoro-4-methoxy-phenyl)-meth-(E)-ylidene]-hydrazide 
• 118958-80-8 2-fluoro-1-methoxy-4-(2-nitrovinyl)benzene 
• 139613-34-6 C₉H₁₁FN₄O₂*C₇H₈O₃S 
• 84562-30-1 N²-<2,6-dichloro-4-<(3-fluoro-4-methoxybenzylidene)amino>phenyl>-N¹,N¹-dimethylformamidine 
• 66659-67-4 bis(3-fluoro-4-methoxy)benzoin 
• 136030-53-0 (2R,3S)-3-(3'-fluoro-4'-methoxyphenyl)serine 
• 118958-80-8 (trans)-2-fluoro-1-methoxy-4-(2-nitrovinyl)benzene 

Relevant articles and documents

Highly selective copper-catalyzed oxidation of benzyl alcohols to aromatic aldehydes in water at room temperature

Water-soluble 2N2O–Cu(II) complexes were synthesized and used for the catalytic oxidation of benzylic alcohols to the corresponding aldehydes in pure water resulting in high yields of up to 94%. Importantly, the catalytic system exhibits a wide substrate scope, high functional group tolerance and can be reused directly for subsequent reaction cycles. Using this catalytic system, the product 4-methylbenzaldehyde can be produced on a multi-gram scale and in the complete absence of any organic solvent, surfactant or phase transfer reagent. Copyright

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF TUMORS

The present invention relates to compounds of Formula (Ia) or pharmaceutically acceptable salts, hydrates, solvates, clathrates, polymorphs, stereoisomers thereof. It further discloses a pharmaceutical composition comprising compounds of Formula (Ia) and the use of compounds of Formula (Ib), in particular for the use in the treatment of diseases or disorders wherein disrupting Rad51-BRCA2 interaction is beneficial.

Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib

Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small organic molecules (dubbed "fully small-molecule-induced synthetic lethality"). We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncology. We discovered a dihydroquinolone pyrazoline-based molecule (35d) that disrupts the RAD51-BRCA2 protein-protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line. In addition, it synergizes with olaparib (a PARPi) to trigger synthetic lethality. This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.

Direct formylation of fluorine-containing aromatics with dichloromethyl alkyl ethers

Formylations of fluorine-containing aromatic compounds with dichloromethyl alkyl ethers have been investigated. Dichloromethyl propyl ether and dichloromethyl butyl ether have been applied for the formylation of fluorine-containing anisoles to give the corresponding aldehydes in good yields. Application of these ethers is preferable to that of methyl ether, which is prepared from volatile methyl formate. Reaction of fluorine-containing phenols with these dichloromethyl alkyl ethers did not give salicylaldehyde derivatives, leading instead to corresponding aryl formates in high yields. A plausible mechanism is discussed.

Sodium copper chlorophyllin catalyzed chemoselective oxidation of benzylic alcohols and diarylmethanes in water

We report the highly efficient and chemoselective oxidation of benzylic alcohols catalyzed by sodium copper chlorophyllin in water, producing corresponding arylcarbonyl compounds. Importantly, the catalytic system exhibits a wide substrate scope and high functional group tolerance. Moreover, secondary alcohols and even diarylmethanes were smoothly oxidized to the desired aryl ketones with excellent yields.

A simple, mild and efficient oxidation of benzylic alcohols in the presence of NBS/KOAc in aqueous solution

Background: The oxidation of benzylic alcohols to carbonyl compounds is a fundamental reaction in organic synthesis. In traditional oxidation processes, a large amount of toxic and volatile organic solvents and metal oxidants are used. Thus, developing environmentally benign oxidation processes is an important goal. N-Bromosuccinimide (NBS) is an inexpensive and convenient oxidant widely used in a variety of oxidative reactions under acidic or alkaline conditions. Methods: In this paper, we developed a simple, mild, and efficient oxidation of benzylic alcohols in the presence of N-bromosuccinimide (NBS)/KOAc in aqueous solution (H2O/CH2Cl2 = 3:1). Results: A series of benzylic alcohols were oxidized selectively to the corresponding ketones in moderate to excellent yields at room temperature. Conclusion: This reaction was carried out using a wide variety of substrates, required no metal catalyst, and proved to be tolerant towards a variety of different functional groups.

Efficient and Highly Selective Solvent-Free Oxidation of Primary Alcohols to Aldehydes Using Bucky Nanodiamond

Selective oxidation of alcohols to aldehydes is widely applicable to the synthesis of various green chemicals. The poor chemoselectivity for complicated primary aldehydes over state-of-the-art metal-free or metal-based catalysts represents a major obstacle for industrial application. Bucky nanodiamond is a potential green catalyst that exhibits excellent chemoselectivity and cycling stability for the selective oxidation of primary alcohols in diverse structures (22 examples, including aromatic, substituted aromatic, unsaturated, heterocyclic, and linear chain alcohols) to their corresponding aldehydes. The results are comparable to reported transition-metal catalysts including conventional Pt/C and Ru/C catalysts for certain substrates under solvent-free conditions. The possible activation process of the oxidant and substrates by the surface oxygen groups and defect species are revealed with model catalysts, ex situ electrochemical measurements, and ex situ attenuated total reflectance. The zigzag edges of sp2 carbon planes are shown to play a key role in these reactions.

NOVEL NUCLEOSIDE PHOSPHORAMIDATE COMPOUND AND USE THEREOF

The present invention provides a novel nucleoside phosphoramidate compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The present invention also provides the pharmaceutical composition comprising a compound of the present invention, or a stereoisomer, salt, hydrate, solvate or crystal thereof and a use of the compound or the composition of the present invention in the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The compound of the present invention has a good anti-HCV effect.

Elemental fluorine. Part 21. (1) direct fluorination of benzaldehyde derivatives

Direct fluorination of a range of benzaldehyde derivatives gives mixtures of fluorobenzaldehyde and benzoyl fluoride products in ratios that depend upon the nature of the ring substituent Electron-withdrawing substituents give predominantly benzoyl fluoride derivatives, whereas electron-donating substituents lead to fluoroarene systems. Separation of ring-fluorinated products can be easily accomplished by esterification of the benzoyl fluoride side products. Scale-up of these processes to provide significant quantities of appropriate fluorobenzaldehyde systems has also been achieved using continuous flow techniques.

Elemental fluorine. Part 20. Direct fluorination of deactivated aromatic systems using microreactor techniques

Continuous flow microreactor technology has been used for the direct fluorination of a range of deactivated di- and tri-substituted aromatic systems.